Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Adagio Medical Holdings, Inc. (ADGM)

Adagio Medical files updated investor presentation with 8-K dated August 13, 2026

Neutral Impact 2 of 5 other Written later

Adagio Medical Holdings furnished an updated corporate presentation for investor, analyst and other meetings, attached as Exhibit 99.1 to a Form 8-K. The filing is a Regulation FD disclosure with no financial results, guidance or transaction terms, so it contains no new reported financial figures.

Key points

  • Updated corporate presentation dated August 13, 2026, made available on the company website and attached as Exhibit 99.1.
  • Presentation cites FDA approval of vCLAS expected Q4 2026 and of next-generation vCLAS Ultra expected Q1 2028, per company timeline.
  • Presentation lists cash and cash equivalents of $7.7 million and convertible notes payable of $24.8 million at June 30, 2026.

The filing

CompanyAdagio Medical Holdings, Inc. (ADGM)
Form8-K, current report
Filed with the SECAug 13, 2026, 4:37 PM ET
Accession number0001104659-26-095987

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.